Fig 2: Combination of SOX and anti-TIGIT is beneficial to CD8+ T cells proliferation and IFN-? release. (a, b) CD8+ TIL cells were treated with SOX, Anti-TIGIT, or SOX +Anti-TIGIT. Immunofluorescence was used to detect expression levels of KI-67. (c, d) CD8+ TIL cells were treated with SOX, Anti-TIGIT, or SOX +Anti-TIGIT, and stimulated with PMA for 5 h. Frequency and number of IFN-? of CD8+ cells were quantified. *P < 0.05, **P < 0.01.

Fig 3: The asscociation between TIGIT expression and GC patients outcome predicted online. (a) GEPIA database prediction of TIGIT expression in different types of tumour tissues and adjacent normal tissues. (b) Expression of TIGIT in gastric cancer (GC) tissues and adjacent normal tissues in GEPIA database. (c) Association between TIGIT expression and stage in GEPIA database. (d) Follow-up was available for the TIGIT expression and overall survival (OS) in Kaplan-Meier Plotter database (P = 9.6e-10). (e) Follow-up was available for TIGIT expression and FP in Kaplan-Meier Plotter database (P = 9.5e-09). (f) Follow-up was available for the TIGIT expression and PPS in Kaplan-Meier Plotter database (P = 1.8e-13). *P < 0.05.

Fig 4: TIGIT is elevated on CD8+T cell in patients with GC and significantly reduced after D2 gastrectomy. (a) Flow cytometry analysis of CD8+ TIGIT+, CD8+PD-1+, or CD8+ TIGIT+PD-1+ T-cell populations in pre- and post-operative PBMC from patients with GC. (b) Frequency and number of CD8+ TIGIT+, CD8+PD-1+, or CD8+ TIGIT+PD-1+ cells in pre-chemotherapy and post-chemotherapy treated PBMC from patients with GC. **P < 0.01.

Fig 5: High TIGIT expression is associated with relapsed GC. (A) Flow cytometry analysis of CD8+ TIGIT+, CD8+PD-1+, or CD8+ TIGIT+PD-1+,or CD8+ TIGIT+PD-1+ T-cell populations in post-chemotherapy and relapse blood from patients with GC. (B) Frequency and number of CD8+ TIGIT+, CD8+PD-1+, or CD8+ TIGIT+PD-1+ T-cell populations in post-chemotherapy and relapse blood from patients with GC (C) The association between CD8+ TIGIT+, CD8+PD-1+, or CD8+ TIGIT+PD-1+ T-cell expression and DFS of GC patients. **P < 0.01, ***P < 0.001.